| [1] |
Ebeling F G, Stieber P, Untch M, et al. Serum CEA and CA15-3 as prognostic factors in primary breast cancer. Br J Cancer,2002,86:1217 -1222.
|
| [2] |
Gion M, Boracchi P, Dittadi R, et al. Prognostic role of serum CA15-3 as in 362 node-negative breast cancers: an old player for a new game. Eur J Cancer ,2002,38:1181 -1188.
|
| [3] |
Khatcheressian J L, Wolff A C, Smith T J, et al. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol ,2006,24:5091 -5097.
|
| [4] |
Molina R, Barak V, van Dalen A, et al. Tumor markers in breast cancer: European Group on Tumor Markers recommendations. Tumour Biol ,2005,26:281 -293.
|
| [5] |
De La Lande B, Hacene K, Floiras J L, et al. Prognostic value of CA 15.3 kinetics for metastatic breast cancer. Int J Biol Markers,2002,17:231 -238.
|
| [6] |
Kokko R, Holi K, Hakama M. Ca15-3 in the follow-up of localized breast cancer: a prospective study. Eur J Cancer,2002,38:1189 -1193.
|
| [7] |
Molia R, Filella X A. Prospecctive,evaluation of CEA and CA15-3 inpatients with locoregional breast cancer. Anticancer,2003,23:1035 -1041.
|
| [8] |
Lama G , Angelucci C , Bruzzese N ,et al . Sensitivity of human melanoma cells to oestrogens, tamoxifen and quercetin:is there any relationship with type I and II oestrogen binding site expression? Melanoma Res,1998,8:313 -322..
|
| [9] |
李树玲. 乳腺肿瘤学. 北京: 科学技术文献出版社,2000:306.
|
| [10] |
Colozza M, Azambuja E, Cardoso F, et al. Proliferative markers as prognostic and predictive tools in early breast cancer:Where are we now? Ann Oncol,2005,16:1723 -1739.
|
| [11] |
Michels J J, Duigou F,Marnay J. Flow cytometry in primary breast carcinomas:prognostic impact of proliferative activity.Breast Cancer Res Treat,2000,62:117 -126.
|
| [12] |
Colozza M, Azambuja E, Cardoso F, et al. Proliferative markers as prognostic and predictive tools in early breast cancer:Where are we now? Ann Oncol,2005,16:1723 -1739.
|
| [13] |
Slamon D J, Clark G M, Wong S G, et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science,1987,235:177 -182.
|
| [14] |
Romond E H, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER-2 positive breast cancer, N Engl J Med,2005,353:1673 -1684.
|
| [15] |
Slamon D J, Leyland Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER-2 for metastatic breast cancer that overexpresses HER-2. N Engl J Med,2001,344:783 -792.
|
| [16] |
Buzdar A U, Ibrahim N K, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzurnab, pachtaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor positive operable breast cancer. J Clin Oncol,2005,23 :3676 -3685.
|
| [17] |
Geyer C E, Forster J, Lindpuist D, et al: Lapatinib plus capecitabine for HER-2-positive advanced breast cancer. N Engl J Med ,2006,355:2733 -2743.
|
| [18] |
Miles D W, Harris W H, Gillett C E, et al. Effect of c-erbB(2) and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil. Int J Cancer,1999,84:354 -359.
|
| [19] |
J arvinen T A , Tanner M , Rantanen V , et al . Amplification and deletion of topoisomerase Iialpha associate with HER-2 amplification and affect sensitivity to topoisomerase Ⅱinhibitor doxorubicin in breast cancer. Am J Pathol, 2000,156:839 -847.
|
| [20] |
Isola J J, Tanner M, Holli K, et al. Amplification of topoisomerase Ⅱalpga is a strong predicator of response to epirubicin-based chemotherapy in HER-2/neu positive metastatic breast cancer. Proc Breast Cancer Res Treat,2000,64:31.
|
| [21] |
Dati C, Antoniotti S, Taverna D, et al. Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells. Oncogene,1990,5:1001 -1006.
|
| [22] |
Ellis M J, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2positive, estrogen receptor-positive primary breast cancer: evidence from a phase Ⅲrandomized trial. J Clin Oncol,2001,19:3808 -3816.
|
| [23] |
Dowsett M, Allred D C. Relationship between quantitative ER and PgR expression and HER-2 status with recurrence in the ATAC trial. San Antonio, TX:San Antonio Breast Cancer Symposium,2006.
|
| [24] |
Silvestrini R, Benini E, Daidone M G, et al. p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst,1993,85 :965 -970.
|
| [25] |
Olivier M, Langerod A, Carrieri P, et al. The clinical value of somatic TP53 gene mutations in 1794 patients with breast cancer. Clin Cancer Res,2006,12:1157 -1167.
|
| [26] |
Rochefort H, Garcia M, Glondu M, et al. Cathepsin D in breast cancer: mechanisms and clinical applications: a 1999 overview . Clin Chim Acta,2000,291:157 -170.
|
| [27] |
Janicke F, Prechtl A, Thomssen C, et al. Randomized adjuvant chemotherapy trial in high risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst,2001,93:913 -920.
|
| [28] |
Rochefort H, Liaudet-Coopman E, Beaujouin M, et al. Cathepsin D: newly discovered functions of a long-standing aspartic protease in cancer and apoptosis. Cancer Lett,2006,18:167 -179.
|
| [29] |
Foekens J A,Look M P,Boltde Vries J,et al. Cathepsin-D in primary breast cancer:prognostic evaluation involving 2810 patients. Br J Cancer,1999,79:300 -307.
|
| [30] |
Billgren A M, Tani E, Liedberg A, et al. Prognostic significance of tumor cell proliferation analyzed in fine needle aspirates form primary breast cancer. Breast Cancer Res Treat,2002,71:161 -170.
|
| [31] |
Ford H L , Kabingu E N , Bump E A , et al . Abrogation of the G-cell cycle checkpoint associated with overexpression of HSIX1: a possible mechanism of breast carcinogenesis. Proc Natl Acad Sci USA,1998,95:12 608 -12 613.
|
| [32] |
Wang L, Shao Z M. Cyclin e expression and prognosis in breast cancer patients:A meta-analysis of published studies.Cancer lnvest,2006,24:581 -587.
|
| [33] |
Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative ,estrogen receptor-positive breast cancer. J Clin Oncol,2006 ,24:3726 -3734.
|
| [34] |
Paik S, Shak S,Tang G,et al. A multigene assay to predict recurrence of tamoxifen-treated,node-negative breast cancer.N Engl J Med,2004,351:2817 -2826.
|
| [35] |
Hable L A, Puesenberry C P, Jacobs M K, et al. Large case-control study of gene expression and breast cancer death in the Northern California Kaiser Permanente population. San Antonio, TX: Antonio Breast Cancer Symposium,2004.
|
| [36] |
Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol,2006,24:3726 -3734.
|